← 返回前沿论文

恶性脑肿瘤中的免疫:肿瘤类型、免疫治疗的作用及髓系细胞对脑肿瘤微环境的特定贡献

英文原题:Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment.

查看英文原题

Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment.

PubMed 2023/12/11(内容时间) Eur J Immunol Q2 · IF 4.1(JCR 2025)

研究概要

恶性脑肿瘤缺乏有效治疗手段,无法改善标准治疗所取得的较差总生存期。

中文摘要

恶性脑肿瘤缺乏能够改善标准治疗下较差总生存的有效疗法。不同癌症治疗领域的进展,使脑肿瘤研究和临床试验重点转向免疫治疗。对免疫细胞组成的研究发现,肿瘤微环境中髓系细胞占主导地位,其确切作用和功能仍在研究中。现有证据提示,肿瘤细胞与髓系细胞之间存在复杂相互作用;它们在促进或控制肿瘤生长方面发挥彼此竞争的功能。本文简要概述三种最常见的脑肿瘤类型:脑膜瘤、胶质瘤及脑转移瘤。我们还介绍正在进行的免疫治疗试验及其结果,包括免疫检查点抑制剂、疫苗研究、溶瘤病毒治疗和CAR-T细胞。最后总结小胶质细胞、单核细胞来源巨噬细胞、脑边界相关巨噬细胞、中性粒细胞的表型,并讨论潜在的新治疗靶点。

展开英文摘要原文

Malignant brain tumors lack effective treatment, that can improve their poor overall survival achieved with standard of care. Advancement in different cancer treatments has shifted the focus in brain tumor research and clinical trials toward immunotherapy-based approaches. The investigation of the immune cell landscape revealed a dominance of myeloid cells in the tumor microenvironment. Their exact roles and functions are the subject of ongoing research. Current evidence suggests a complex interplay of tumor cells and myeloid cells with competing functions toward support vs. control of tumor growth. Here, we provide a brief overview of the three most abundant brain tumor entities: meningioma, glioma, and brain metastases. We also describe the field of ongoing immunotherapy trials and their results, including immune checkpoint inhibitors, vaccination studies, oncolytic viral therapy, and CAR-T cells. Finally, we summarize the phenotypes of microglia, monocyte-derived macrophages, border-associated macrophages, neutrophils, and potential novel therapy targets.

论文信息

作者
Kienzler JC、Becher B
单位
Institute of Experimental Immunology, Inflammation Research Lab, University of Zurich, Zurich, Switzerland.Switzerland
文献类型
综述 · 非美国政府资助研究
期刊
European journal of immunology2024 Feb
原文标识
PubMed 37940552 · DOI 10.1002/eji.202250257